Page last updated: 2024-12-06
succinic dihydrazide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
succinic dihydrazide: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 72491 |
| CHEMBL ID | 3091861 |
| SCHEMBL ID | 220310 |
| MeSH ID | M0174929 |
Synonyms (56)
| Synonym |
|---|
| BB 0240688 |
| butanedioyl dihydrazide |
| succinic acid dihydrazide |
| nsc42940 |
| nsc-42940 |
| nsc-29540 |
| nsc29540 |
| succinyl dihydrazide |
| 4146-43-4 |
| succinic dihydrazide |
| nsc25180 |
| succinic acid hydrazide |
| succinic acid, dihydrazide |
| succinhydrazide |
| nsc-25180 |
| butanedioic acid, dihydrazide |
| butanedihydrazide |
| succinohydrazide |
| succinic hydrazicle |
| succinic dihydrazide, 96% |
| nsc 29540 |
| brn 1775110 |
| nsc 42940 |
| nsc 25180 |
| succinoyldihydrazine |
| einecs 223-970-9 |
| STK022351 |
| AKOS000267173 |
| inchi=1/c4h10n4o2/c5-7-3(9)1-2-4(10)8-6/h1-2,5-6h2,(h,7,9)(h,8,10) |
| hcomfayphbfmku-uhfffaoysa- |
| butanediohydrazide |
| S0482 |
| A825564 |
| butanedioic acid dihydrazide |
| unii-h3wmy7s4lo |
| 4-02-00-01925 (beilstein handbook reference) |
| h3wmy7s4lo , |
| FT-0635154 |
| CHEMBL3091861 |
| SCHEMBL220310 |
| BBL035998 |
| succinohydrazide # |
| HCOMFAYPHBFMKU-UHFFFAOYSA-N |
| c4h10n4o2 |
| F1943-0022 |
| DTXSID10194363 |
| mfcd00007613 |
| succinic acid dihydrazone |
| butanedioic acid, 1,4-dihydrazide |
| sudh |
| succinic acid, hydrazide |
| AMY3980 |
| AS-56728 |
| CS-0149895 |
| succinic dihydrazide;butanedioyl dihydrazide |
| E81949 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Bioassays (2)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1059233 | Antitubercular activity against Mycobacterium tuberculosis BCG | 2013 | European journal of medicinal chemistry, , Volume: 70 | Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds. |
| AID1059234 | Lipophilicity, log P of the compound | 2013 | European journal of medicinal chemistry, , Volume: 70 | Comparison of Multiple Linear Regressions and Neural Networks based QSAR models for the design of new antitubercular compounds. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 22.95
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (22.95) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||